JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on Reconciliation of Natural Product Bioactivity, Pharmacokinetic Roadblocks, and Ethnopharmacogenomics in Oncology

Leo Tata[1], Ugonna Chidiebere Metu[2], Rita Onyebuchi Ogboh*[3], Ndidi Atasie Eboh[4], Uchechukwu Lilian Okoye[5], Bassey Atte Inyang[6]

[1] *College of Health and Human Sciences, Iowa State University, Ames, Iowa, USA*
[2] *Department of Biochemistry, University of Cross River State, Calabar, Nigeria*
[3] *Department of Pharmacology and Toxicology, Niger Delta University, Bayelsa State, Nigeria*
[4] *Department of Nursing, Stark State College, North Canton, Ohio, USA*
[5] *Department of Chemistry, Georgia Southern University, Georgia, USA*
[6] *Department of Medical Biochemistry, College of Health Sciences, University of Abuja, Federal Capital Territory, Nigeria*

Publication history: Received on 4th April 2026; Revised on 10th May 2026; Accepted on 11th May 2026

Article DOI: 10.69613/86d00061

Abstract: Cancer disparities in low- and middle-income countries remain severe due to the prohibitive costs and infrastructural requirements of next-generation sequencing and targeted molecular biologics. While traditional botanical medicine offers a vast, structurally different reservoir of bioactive secondary metabolites, translating these traditional resources into clinically validated oncological interventions requires a rigorous scientific study. This review presents the conceptual and practical integration of ethnopharmacological knowledge with tumor genomic profiling and host pharmacogenomics. *In vitro* studies show that major classes of plant-derived compounds, including alkaloids, polyphenols, terpenoids, and organosulfur molecules, modulate key oncogenic cascades such as the PI3K/AKT/mTOR, MAPK/ERK, and NF-κB pathways. However, the clinical translation of these benefits is severely constrained by profound pharmacokinetic barriers. Rather than host genetic variation in drug-metabolizing enzymes, the primary impediments to clinical efficacy for prominent compounds like curcumin and withaferin A are extremely low aqueous solubility, rapid Phase-II glucuronidation, chemical instability, and prominent Pan-Assay Interference Compounds characteristics. Reconciling these physical and metabolic limitations requires an objective evaluation of herb-drug interactions, standardized phytochemical profiling, and the implementation of host-tumor genomic stratification. Researchers can systematically categorize compound-target interactions and prioritize candidates for rigorous validation by utilizing computational approaches such as structural molecular docking, network pharmacology, and machine learning. Cultivating an ethically sound, epistemologically just translational pipeline in resource-limited settings necessitates clear regulatory guidelines, standardized quality controls, and equitable benefit-sharing arrangements that protect indigenous intellectual property.

Keywords: Ethnopharmacogenomics; Precision Oncology; Bioavailability; Glucuronidation; Pharmacokinetics.

1. Introduction

Global oncological data indicates that cancer is one of the most pressing public health challenges, with approximately 19.3 million new diagnoses and nearly 10 million deaths recorded in a single calendar year [1]. The burden of this mortality falls disproportionately on low- and middle-income countries (LMICs), where population aging, environmental exposures, and rapid lifestyle transitions intersect with severely limited diagnostic and therapeutic infrastructure. In high-income countries, the clinical management of malignant neoplasms has transitioned toward precision oncology, which utilizes next-generation sequencing (NGS), transcriptomic profiling, and targeted molecular therapies to tailor interventions to the genetic architecture of individual tumors [2], [3]. Despite the clinical success of these targeted agents, their implementation remains highly unequal. The high cost of molecular diagnostics, the scarcity of specialized bioinformatics pipelines, and the prohibitive pricing of targeted monoclonal antibodies and small-molecule inhibitors render these advancements virtually inaccessible to the vast majority of patients across sub-Saharan Africa, South Asia, and Latin America [4], [5].

This profound therapeutic disconnect shows the necessity of exploring alternative, contextually accessible pathways for drug discovery and clinical management. Traditional medicinal systems, which utilize botanical formulations and complex natural product mixtures, continue to serve as the primary source of healthcare for substantial portions of the population in LMICs [6], [7].

* Corresponding author: Rita Onyebuchi Ogboh

Copyright © 2026 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution License 4.0.

Historically, natural products have served as an invaluable source of chemical scaffolds for oncological drug discovery. Major chemotherapeutic agents, including microtubule-stabilizing taxanes, tubulin-depolymerizing vinca alkaloids, and topoisomerase-inhibiting camptothecin derivatives, were isolated directly from plants utilized in traditional medical contexts [8]. However, much of the contemporary clinical use of traditional botanical medicines in oncology remains unstructured, lacking systematic pharmacological characterization, quality control, and scientific validation.

The emergence of high-throughput analytical technologies, metabolomic profiling, and computational systems biology offers an unprecedented opportunity to evaluate traditional medicines with molecular rigor. Rather than accepting traditional claims without empirical support or dismissing them as unscientific, a systematic framework is required to investigate the biological mechanisms, pharmacokinetic limitations, and host-specific factors that govern the activity of plant-derived compounds. A critical aspect of this investigation is the wide inter-individual variability observed in patient responses to botanical therapeutics. This variability is driven by a complex interplay between host pharmacogenomic diversity, which influences drug disposition and transport, and the distinct somatic mutational profiles of individual tumors, which dictate pathway dependencies and therapeutic sensitivity [9], [10].

This review evaluates the scientific evidence surrounding the usage of ethnopharmacological knowledge with modern precision oncology and host pharmacogenomics. It addresses the mechanistic foundations of major phytochemical classes, analyzes the primary pharmacokinetic and pharmacodynamic barriers to clinical translation, and outlines the computational tools utilized to model herb-gene-tumor interactions. It details the methodological, regulatory, and ethical guidelines required to transform ethnopharmacogenomics from an exploratory preclinical methodology into a safe, evidence-based, and contextually appropriate clinical reality for populations underserved by conventional precision medicine.

2. Plant-Derived Anticancer Agents

2.1. Structural Diversity and the Lead Discovery

Natural products possess unique chemical characteristics that distinguish them from synthetic small-molecule libraries. Evolutionary pressures have selected for plant secondary metabolites that interact specifically with biological macromolecules, resulting in high structural complexity, stereochemical richness, a high count of oxygen atoms, and a high proportion of sp^3-hybridized carbon atoms [11]. These attributes endow natural products with a superior capacity to target complex protein-protein interfaces and regulatory nodes within eukaryotic signaling networks. Retrospective analyses of food and drug administration approvals confirm that more than half of all approved small-molecule anticancer therapeutics are either unmodified natural products, botanical derivatives, or synthetic compounds built directly upon natural product pharmacophores [12]. Ethnobotanical documentation serves as an empirical guide within this discovery pipeline, accelerating the identification of biologically active leads by selecting species with a history of therapeutic utility rather than relying on non-directed, high-throughput screening of synthetic compound libraries [13].

2.2. Major Phytochemical Classes and Molecular Actions

The biological activities of plant-derived compounds are attributed to distinct chemical classes, each operating through defined, though often pleiotropic, intracellular mechanisms.

2.2.1. Alkaloids

Nitrogenous plant secondary metabolites, or alkaloids, represent some of the most potent antineoplastic agents identified to date. The bisindole alkaloids vincristine and vinblastine, isolated from *Catharanthus roseus*, bind specifically to tubulin heterodimers, preventing their polymerization into functional microtubules [14]. This disruption prevents spindle assembly during the mitotic phase of the cell cycle, triggering cell-cycle arrest at the metaphase-anaphase transition and initiating apoptosis via the activation of caspase-3 and caspase-9 cascades. Similarly, berberine, a quaternary isoquinoline alkaloid found in *Berberis* species, exhibits multi-targeted regulatory activity. Preclinical assays indicate that berberine intercalates into DNA, inhibits topoisomerase enzymes, and suppresses the signaling of nuclear factor kappa B (NF-κB), thereby reducing the transcription of pro-survival, anti-apoptotic, and metastatic genes in colorectal and breast cancer cell models [15].

2.2.2. Polyphenols

Characterized by the presence of multiple phenolic rings, polyphenols modulate tumor cell biology by altering epigenetic patterns, oxidative stress states, and receptor tyrosine kinase signaling. Curcumin, the primary hydrophobic polyphenol from *Curcuma longa*, has been shown in cell culture models to suppress the activation of IκB kinase (IKK), thereby preventing the nuclear translocation of the p65 subunit of NF-κB [16]. Resveratrol, a stilbenoid found in *Vitis vinifera*, acts as a mimetic of caloric restriction and activates sirtuin-1 (SIRT1), which in turn deacetylates and stabilizes the tumor suppressor protein p53, promoting transcription of the pro-

apoptotic B-cell lymphoma-2-associated X protein (Bax) [17]. Epigallocatechin gallate (EGCG), the dominant catechin in *Camellia sinensis*, inhibits the activation of the epidermal growth factor receptor (EGFR) and downregulates the expression of DNA methyltransferase 1 (DNMT1), which can lead to the transcriptional reactivation of silenced tumor suppressor genes *in vitro* [18].

2.2.3. Terpenoids

This structurally diverse group of hydrocarbons, derived from isoprene units, includes paclitaxel, a tetracyclic diterpenoid isolated from *Taxus brevifolia*. Unlike the vinca alkaloids, paclitaxel binds specifically to the β-subunit of tubulin, promoting microtubule assembly and preventing depolymerization, which freezes the mitotic spindle and forces cell death [19]. Other terpenoids, such as the triterpenoid saponins known as ginsenosides from *Panax ginseng*, show anti-angiogenic properties in endothelial co-culture assays by suppressing the phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2) and downstream mitogen-activated protein kinase (MAPK) pathways [20].

2.2.4. Organosulfur Compounds and Withanolides

Organosulfur molecules, such as allicin and diallyl disulfide from *Allium sativum*, modulate phase-II detoxification enzymes, upregulate intracellular glutathione levels, and induce G2/M cell-cycle arrest in gastric cancer models [21]. Withanolides, primarily withaferin A from *Withania somnifera*, represent a class of steroidal lactones that bind directly to heat shock protein 90 (Hsp90). This binding destabilizes Hsp90 client proteins, including mutated p53, AKT, and Raf-1, leading to their proteasomal degradation and subsequent cell death [22]. A summary of some medicinal plants, their bioactive constituents, and preclinical molecular mechanisms is presented in Table 1.

Table 1. Bioactive constituents, and preclinical molecular mechanisms of some medicinal plants

Plant Species	Primary Bioactive Compound	Preclinical Cancer Models	Primary Preclinical Mechanism of Action	Reference
Taxus brevifolia	Paclitaxel	Breast, Ovarian, Non-Small Cell Lung	Microtubule stabilization; mitotic arrest	[19]
Catharanthus roseus	Vincristine, Vinblastine	Leukemia, Lymphoma, Solid Tumors	Tubulin depolymerization; mitotic spindle disruption	[14]
Curcuma longa	Curcumin	Colorectal, Breast, Pancreatic	IKK/NF-κB pathway inhibition; apoptosis induction	[16]
Camptotheca acuminata	Camptothecin	Colorectal, Ovarian	Topoisomerase I inhibition; DNA double-strand breaks	[8]
Withania somnifera	Withaferin A	Prostate, Breast, Glioblastoma	Hsp90 inhibition; proteasomal degradation of oncogenic clients	[22]
Berberis vulgaris	Berberine	Colorectal, Breast	AMPK activation; NF-κB pathway suppression	[15]
Panax ginseng	Ginsenoside Rg3	Lung, Gastric, Melanoma	VEGFR2 phosphorylation inhibition; anti-angiogenesis	[20]
Vitis vinifera	Resveratrol	Breast, Colorectal, Prostate	SIRT1-mediated p53 activation; Bax upregulation	[17]
Camellia sinensis	EGCG	Breast, Prostate, Colon	EGFR kinase inhibition; DNMT1 downregulation	[18]
Allium sativum	Allicin, Diallyl disulfide	Gastric, Colorectal	Phase-II enzyme induction; G2/M cell-cycle arrest	[21]

2.3. Oncogenic Pathways and Target Node Ambiguities

In vitro studies frequently show that plant-derived compounds target a highly conserved set of signaling nodes. The PI3K/AKT/mTOR cascade, which is constitutively activated in numerous human malignancies through PIK3CA mutations or PTEN loss, is a frequent target of phytochemical modulation [23]. Compounds such as quercetin and curcumin inhibit the phosphorylation of AKT and downstream mTOR complex 1 (mTORC1) in cell culture lines, mimicking the effects of synthetic kinase inhibitors. Similarly, the MAPK/ERK pathway, frequently driven by oncogenic KRAS or BRAF mutations, is suppressed by resveratrol and berberine through the downregulation of extracellular signal-regulated kinase (ERK) phosphorylation [24]. The transcription factor NF-κB, which links chronic inflammation with tumor promotion and chemoresistance, represents a common target for polyphenols and sesquiterpene lactones, which prevent its nuclear translocation and subsequent activation of anti-apoptotic genes [16].

However, interpreting these preclinical mechanisms requires extreme caution. The apparent multi-targeted or pleiotropic activity of these compounds in cell cultures is frequently a consequence of non-specific physicochemical interactions rather than high-affinity, target-directed engagement. Many heavily studied phytochemicals exhibit Pan-Assay Interference Compounds (PAINS) behavior, characterized by covalent reactivity, metal chelation, membrane disruption, fluorescence interference, and protein aggregation in assays [25]. Consequently, the reported downregulation of an oncogenic pathway in an *in vitro* system may reflect generalized chemical stress or assay artifact rather than a therapeutically viable, target-specific pharmacological inhibition. Distinguishing genuine, high-affinity target engagement from promiscuous assay interference remains a major hurdle that must be resolved prior to proposing any translational integration with precision oncology pathways.

Table 2. Targeted Oncogenic Cascades, Phytochemical Modulators, and Somatic Biomarkers

Phytochemical Class	Bioactive Compound	High-Affinity Molecular Target(s)	Associated Somatic Tumor Alteration	Intended Biological Outcome	References
Alkaloid	Berberine	AMPK, DNA Topoisomerase-II, Wnt/β-catenin	*APC* mutations, *CTNNB1* mutations, *KRAS* mutations	Activation of AMPK, suppression of β-catenin transcriptional activity, G1-phase cell-cycle arrest	[15]
Polyphenol	Curcumin	IκB Kinase (IKK), STAT3, AKT	*PIK3CA* mutations, *PTEN* deletion, *EGFR* amplification	Inhibition of NF-κB nuclear translocation, downregulation of Bcl-2, induction of mitochondrial apoptosis	[16], [22]
Polyphenol	Epigallocatechin gallate (EGCG)	DNMT1, EGFR Kinase Domain, VEGFR2	*EGFR* mutations, *VEGFA* overexpression, *BRCA1* methylation	Reversal of promoter hypermethylation, restoration of tumor suppressor expression, inhibition of angiogenesis	[18], [20]
Terpenoid	Withaferin A	Heat Shock Protein 90 (Hsp90), Proteasome β5 subunit	*TP53* mutations (gain-of-function), *EGFRvIII* mutant	Ubiquitin-mediated degradation of Hsp90 client proteins (mutated p53, AKT, Raf-1)	[19], [22]
Stilbenoid	Resveratrol	Sirtuin-1 (SIRT1), Cyclooxygenase-2 (COX-2)	*TP53* wild-type, *PIK3CA* mutations, inflammatory stroma	SIRT1-mediated p53 deacetylation and stabilization, transcriptional downregulation of pro-survival factors	[17], [24]

3. Pharmacokinetic Barriers and Pharmacogenomic Diversity

3.1. Bioavailability Bottleneck

The principal barrier preventing the clinical translation of most plant-derived compounds is not host genetic variability, but rather their inherently poor, often negligible baseline bioavailability. This limitation is exemplified by curcumin, which despite showing nanomolar potency in cell-based assays, exhibits dismal therapeutic levels *in vivo* [26].

3.1.1. Physicochemical Limitations

Poor aqueous solubility significantly restricts the dissolution of hydrophobic compounds in the gastrointestinal tract. Under physiological conditions, curcumin, resveratrol, and withaferin A possess low thermodynamic solubility, preventing the achievement of concentration gradients necessary for passive transcellular absorption across the enterocyte membrane. Many of these molecules exhibit poor chemical stability at physiological pH. Curcumin degrades rapidly via autoxidation and hydrolytic cleavage at pH values above 7.0, generating a complex mixture of degradation products, which further minimizes the fraction of intact, biologically active parent compound available for systemic absorption [27].

3.1.2. Pre-systemic Clearance and Glucuronidation

Even the small fraction of these compounds that crosses the intestinal epithelium is subjected to rapid and extensive first-pass metabolism. The intestinal mucosa and hepatocytes express high levels of Phase-II conjugating enzymes, specifically UDP-glucuronosyltransferases (UGTs) and sulfotransferases (SUTs). Curcumin, resveratrol, and quercetin are excellent substrates for UGT1A1, UGT1A8, and UGT1A9, which rapidly convert the parent polyphenols into hydrophilic glucuronide and sulfate conjugates [28]. These Phase-II metabolites generally lack the affinity of the parent compounds for oncogenic targets and are rapidly cleared from circulation via biliary and renal excretion. Consequently, oral administration of these compounds fails to yield systemic plasma concentrations capable of matching the micromolar concentrations required to inhibit oncogenic targets in *in vitro* systems.



Figure 1. Pharmacokinetic Barriers & Oral Bioavailability Bottleneck

3.2. Host Pharmacogenomics and ADME Variation

While baseline physicochemical constraints represent the dominant barrier, genetic polymorphisms in the host metabolic and transport machinery introduce an additional layer of pharmacokinetic variability.

3.2.1. Cytochrome P450 Polymorphisms

Phase-I oxidation of several alkaloid and terpenoid compounds is mediated by the cytochrome P450 (CYP) superfamily, which exhibits extensive genetic variation across different human populations [29]. For example, berberine is metabolized primarily by CYP2D6, CYP1A2, and CYP3A4. Individuals carrying loss-of-function alleles for CYP2D6 (such as CYP2D6*4 or *5, common in European populations) or reduced-function alleles (such as CYP2D6*10 or *17, prevalent in East Asian and African populations) exhibit significantly reduced clearance of the parent compound, leading to elevated systemic exposure [30]. Conversely, ultra-rapid metabolizers carrying CYP2D6 gene duplications clear the compound rapidly, potentially nullifying any therapeutic effect. Similarly, variations in CYP3A4 expression and activity, such as the CYP3A4*22 allele, modify the systemic clearance of paclitaxel and other plant-derived diterpenes, directly influencing the risk of dose-limiting toxicities such as peripheral neuropathy [29].

3.2.2. Transporter-Mediated Efflux

ATP-binding cassette (ABC) efflux transporters, located on the apical membrane of enterocytes, hepatocytes, and renal tubular cells, restrict the systemic absorption of numerous phytochemicals. P-glycoprotein (P-gp, encoded by ABCB1) and Breast Cancer Resistance Protein (BCRP, encoded by ABCG2) actively pump compounds like berberine, curcumin, and resveratrol back into the intestinal lumen, further limiting their oral bioavailability [31]. The ABCB1 single nucleotide polymorphism C3435T and the ABCG2

variant C421A (which codes for a protein with reduced efflux capacity) significantly alter the pharmacokinetic profiles of these substrates. Patients homozygous for the ABCG2 421A allele exhibit substantially higher plasma concentrations of BCRP substrates, which can enhance systemic exposure but also elevate the risk of systemic toxicities when co-administered with conventional chemotherapeutic agents that share these transporter pathways [31].

Table 3. Host Germline ADME Pharmacogenomic Variants and Phytochemical Disposition

Enzyme / Transporter Family	Specific Genetic Locus	Prevalent Allelic Variant(s)	Impact on Enzyme / Transporter Function	Affected Phytochemical Substrate(s)	Systemic Pharmacokinetic Outcome	References
Cytochrome P450	*CYP2D6*	*4, *5 (null activity); *10, *17 (reduced activity)	Abolished or severely diminished Phase-I oxidative demethylation	Berberine	Impaired metabolic clearance, prolonged plasma half-life, systemic accumulation, increased risk of dose-dependent hepatotoxicity	[29], [30]
Cytochrome P450	*CYP3A4*	*22 (reduced transcription)	Decreased Phase-I oxidation and hydroxylation	Curcumin, Withaferin A	Elevated exposure to parent compounds, increased potential for off-target systemic receptor interactions	[16], [29]
Phase-II Conjugation	*UGT1A1*	*28 (TA7 promoter insertion)	Reduced glucuronide conjugation activity (Phase-II)	Resveratrol, Quercetin, Curcumin	Impaired conversion to hydrophilic conjugates, increased persistence of free parent compounds, risk of severe diarrhea when competing with SN-38	[28]
ABC Efflux Transporter	*ABCG2*	C421A (Q141K variant)	Reduced apical membrane efflux capacity in enterocytes and hepatocytes	EGCG, Resveratrol, Berberine	Increased fractional absorption across the intestinal barrier, heightened baseline oral bioavailability, risk of transport-mediated drug displacement	[31]
ABC Efflux Transporter	*ABCB1*	C3435T (altered translation speed)	Decreased P-glycoprotein efflux function and tissue protection	Berberine, Paclitaxel	Increased accumulation of substrates in healthy tissues, elevated risk of peripheral neurotoxicity or intestinal mucosa damage	[31]

3.3. Pharmacodynamic Variation and Tumor Genomic Context

The therapeutic efficacy of any bioavailable natural compound is fundamentally dependent on the somatic mutational landscape of the target tumor. This interaction represents the core scientific rationale for precision oncology, yet it is frequently oversimplified in ethnopharmacological literature.

3.3.1. Oncogenic Addiction and Pathway Redundancy

A major error in preclinical translation is the assumption that *in vitro* inhibition of a pathway node, such as PI3K/AKT by quercetin, translates directly to clinical response in a patient with a PIK3CA-mutant tumor. Human cancers are complex, adaptive networks characterized by extensive pathway crosstalk, feedback loops, and redundancy [3]. For instance, colorectal tumors harboring activating mutations in the KRAS gene exhibit constitutive activation of the downstream MAPK cascade. Inhibiting an upstream receptor tyrosine kinase, such as EGFR, using a compound like EGCG, is clinically ineffective in these tumors because the downstream node remains active [24]. Similarly, tumors with PTEN loss or activating PIK3CA mutations exhibit persistent activation of downstream mTOR signaling, which can rapidly bypass single-node inhibition through the upregulation of

compensatory pathways such as the MAPK or JAK/STAT cascades. Consequently, co-prescribing plant-derived agents based solely on an NGS profile, without considering pathway rewiring and adaptive resistance, lacks scientific validity.

3.3.2. Tumor Suppressor Mutations and Downstream Execution

The status of tumor suppressor pathways, particularly p53, represents another critical determinant of pharmacodynamic response. Many plant-derived compounds are reported to induce apoptosis by stabilizing p53 and promoting the transcription of pro-apoptotic genes [17]. However, the majority of advanced human cancers harbor inactivating mutations in the TP53 gene, often resulting in dominant-negative or gain-of-function mutant proteins that are completely resistant to conventional p53-stabilizing signals. In these genetic contexts, compounds that rely on an intact p53 pathway to execute cell death will fail to exhibit therapeutic efficacy. While some phytochemicals have been shown to induce p53-independent apoptosis via the direct activation of mitochondrial outer membrane permeabilization or endoplasmic reticulum stress pathways, these mechanisms must be rigorously validated in genotype-characterized models before any clinical assumptions can be made.

3.3.3. Epigenetic and Microenvironmental Modulation

Beyond somatic mutations, the pharmacodynamic response is heavily modulated by epigenetic alterations and the cellular microenvironment. Aberrant DNA methylation and histone modifications alter the expression of drug receptors, metabolic enzymes, and transport proteins within the tumor mass, leading to localized drug resistance. Although certain polyphenols, including EGCG and genistein, show DNMT-inhibiting or histone deacetylase (HDAC)-modulating properties in preclinical assays, the concentration required to achieve meaningful transcriptional reprogramming *in vivo* is rarely attainable due to the aforementioned pharmacokinetic barriers [18]. Microenvironmental factors such as hypoxia, high extracellular acidity, and dense stromal barriers restrict the physical penetration of hydrophobic phytochemicals into the core of solid tumors. These factors, combined with the presence of immunosuppressive cytokines and tumor-associated macrophages, can completely neutralize the anti-inflammatory or immunomodulatory activities observed in simplified in vitro co-cultures.

4. Computational Approaches to Natural Product–Target Interaction

4.1. Molecular Docking and Virtual Screening

4.1.1. Principles of Ligand-Receptor Simulation

Computational modeling provides an initial pathway for studying the vast chemical space of plant-derived secondary metabolites. Within this framework, molecular docking simulates the geometric and thermodynamic interactions between small-molecule phytochemicals and target proteins of oncological relevance [32]. These algorithms calculate binding free energies, estimate inhibition constants, and identify critical intermolecular forces, such as hydrogen bonding, hydrophobic interactions, π-π stacking, and electrostatic attractions [32]. Researchers can perform high-throughput virtual screens of thousands of plant-derived compounds cataloged in databases like PubChem, ZINC, and the COCONUT natural product library against crystallized human kinases, transcription factors, and epigenetic modulators by utilizing public structural databases such as the Protein Data Bank [33]. This in silico prioritization allows researchers to identify high-affinity scaffolds and formulate mechanistic hypotheses regarding target engagement prior to initiating resource-intensive laboratory experiments.

4.1.2. Limitations of In Silico Binding Affinities

Despite the utility of molecular docking, virtual screening results are frequently prone to overestimating biological efficacy. Standard docking algorithms utilize simplified scoring functions that struggle to accurately model entropy changes, protein flexibility, and the influence of explicit water molecules within the binding pocket [34]. Consequently, high predicted binding affinities in silico frequently fail to correlate with cellular activity. Basic docking procedures do not account for membrane permeability, active efflux, intracellular compartmentalization, or rapid chemical degradation under physiological conditions. A compound exhibiting nanomolar binding affinity to a kinase domain in silico remains therapeutically irrelevant if it is physically excluded from the intracellular environment or rapidly hydrolyzed at physiological pH. Thus, virtual screening is strictly a hypothesis-generating methodology that requires biochemical and biophysical validation, such as surface plasmon resonance or isothermal titration calorimetry, before any therapeutic claims are warranted.

4.2. Network Pharmacology and Pathway Enrichment

4.2.1. Topological Analysis of Herb-Gene Networks

Network pharmacology attempts to transition from the traditional "one drug, one target" paradigm to a systemic "multi-target, multi-pathway" framework, which is particularly relevant to the multi-component nature of botanical preparations [35]. By integrating databases of compound-target interactions with disease-associated gene networks, researchers construct tripartite graphs illustrating the connections between specific medicinal plants, their individual bioactive constituents, and mutated signaling nodes within various cancer types [35]. Network topology analysis utilizing metrics such as degree centrality, betweenness centrality, and closeness centrality identifies key "hub" proteins, such as AKT1, EGFR, TP53, and TNF, that are most densely targeted by a given plant's phytochemical profile [36]. Pathway enrichment analyses utilizing databases like KEGG and Reactome subsequently map these targets to functional cascades, providing a systemic visualization of how a complex natural extract might modulate interconnected oncogenic signaling networks [36].

4.2.2. Multi-Target Mechanisms versus Promiscuity

The apparent multi-target activity highlighted in network pharmacology models must be evaluated with extreme caution. While system-level modulation is theoretically advantageous for overcoming adaptive bypass pathways in heterogeneous tumors, it is frequently difficult to distinguish genuine multi-target synergy from chemical promiscuity and assay interference [25]. Many plant secondary metabolites, particularly polyphenols like curcumin and quercetin, exhibit characteristics of Pan-Assay Interference Compounds (PAINS) [25]. These molecules generate false-positive results in biochemical assays through covalent reactivity, metal chelation, membrane disruption, and light scattering due to colloidal aggregation. When these promiscuous interactions are documented in literature and subsequently imported into network databases, they pollute the computational models with non-specific, clinically irrelevant interactions. Consequently, a network model indicating that a plant extract targets dozens of oncogenic nodes may reflect generalized chemical stress or database noise rather than a coordinated, therapeutically viable pharmacological intervention.

Figure 2. Computational Translation Funnel & Preclinical Reality Gap

4.3. Machine Learning and Predictive Modeling in Phytochemistry

4.3.1. Algorithmic Prediction of Compound-Target Affinities

Supervised machine learning and deep learning models are increasingly utilized to predict compound-protein interactions and pharmacokinetic parameters [37]. By training algorithms on large datasets of annotated small-molecule structures and target-binding profiles, researchers can construct models that predict the biological activities of uncharacterized phytochemicals based on quantitative structure-activity relationship descriptors, molecular fingerprints, or graph neural network representations [37]. These models predict parameters such as blood-brain barrier penetration, human intestinal absorption, and affinity for specific cytochrome P450 isoforms. In the context of ethnopharmacogenomics, machine learning allows for the rapid classification of vast

ethnobotanical datasets, identifying structural analogs of established natural scaffolds that possess superior drug-like properties or reduced susceptibility to rapid clearance mechanisms.

4.3.2. Challenges of Data Heterogeneity and Publication Bias

The application of machine learning to natural product chemistry is severely constrained by the quality and nature of the underlying data. Most public training datasets are heavily biased toward synthetic small molecules and conventional drug targets, meaning that models frequently exhibit poor generalizability when applied to the structurally unique and stereochemically complex scaffolds characteristic of plant secondary metabolites [38]. Ethnopharmacological literature suffers from a profound publication bias, where active compounds and positive screening results are disproportionately published, while inactive molecules and failed assays remain unreported [38]. Training predictive models on datasets lacking high-quality negative data leads to inflated accuracy metrics and high false-positive rates. Additionally, deep learning architectures function as "black boxes," offering high predictive accuracy but lacking the mechanistic transparency required for clinical decision-making and regulatory evaluation in translational oncology.

Table 4. Evaluation of Computational Tools and Public Databases in Ethnopharmacogenomics

Computational Platform	Database / Tool Category	Primary Methodological Application	Specific Strengths in Phytochemistry	Fundamental Methodological Limitations	References
COCONUT / ZINC15	Natural Product Databases	High-throughput virtual ligand library screening	Comprehensive structural catalogs of unique natural plant scaffolds with stereochemical metadata	Static 2D/3D structure files; lacks annotated physiological concentration profiles or biological confirmation	[33]
AutoDock Vina / Glide	Molecular Docking Algorithms	Atomic-level simulation of ligand-receptor binding free energies (ΔG)	Identification of critical hydrogen-bonding and hydrophobic interactions in target pockets	Ignores target pocket flexibility, water-solvent thermodynamics, and trans-membrane cellular kinetics	[32], [34]
cBioPortal / TCGA	Somatic Mutation Registries	Characterization of tumor-specific genomic landscapes and alterations	Direct querying of pathway dysregulations (*KRAS*, *PIK3CA*) and pathway dependency metrics	Completely lacks integration with traditional medicine trials, botanical dosage logs, or clinical phytotherapy outcomes	[24]
KEGG / Reactome	Pathway Enrichment Tools	Topological network mapping and downstream functional annotation	Identifies systemic node clustering and downstream signaling cascades targeted by multicomponent extracts	Relies on historical, synthetic drug annotations; fails to model synergistic or antagonistic phytochemical combinations	[35], [36]
SwissADME / DeepADMET	Machine Learning ADMET Predictors	Deep learning-based forecasting of absorption, distribution, metabolism, and excretion	Rapid QSAR-based prioritization of drug-like phytochemical leads based on chemical descriptors	High rates of false-positives; training models are biased toward synthetic small molecules with poor natural generalizability	[37], [38]

5. Clinical Evidence and Critical Challenges

5.1. The Scientific Rationale for Strategic Co-evaluation

A scientifically valid framework for ethnopharmacogenomics must reconcile two distinct lines of inquiry: the systematic characterization of traditional botanical resources and the somatic mutational profiling of human tumors. This intersection must be mediated by a realistic appraisal of the pharmacokinetic limitations of natural products, recognizing that the principal bottleneck to clinical efficacy is rarely minor host genetic variation, but rather inherently poor baseline bioavailability and rapid metabolic clearance

[26], [28]. The primary utility of integrating these fields is not the immediate, empirical co-prescription of unstandardized plant extracts alongside molecular biologics, but rather the systematic discovery of active scaffolds that can be optimized to engage specific oncogenic pathways. This approach represents a logical pathway for expanding drug discovery resources in settings where expensive targeted therapeutics remain economically inaccessible, provided that preclinical screening is held to the same standards of physical and metabolic validation as synthetic pharmaceuticals.



Figure 3. The Two Converging Branches of Ethnopharmacogenomics

5.2. Methodological Challenges in Phytochemical Standardization

5.2.1. Batch-to-Batch Variability and Chemical Fingerprinting

The inherent chemical complexity of botanical preparations represents a fundamental barrier to generating reproducible scientific evidence. A single plant extract contains hundreds of distinct molecules, the relative concentrations of which vary significantly based on geographic origin, soil composition, altitude, seasonal harvesting periods, post-harvest drying techniques, and extraction solvents [39]. Consequently, two studies evaluating the biological activity of the same plant species may yield contradictory results because the underlying chemical profiles are fundamentally different. Resolving this challenge requires the mandatory implementation of standardized quality control protocols [39]. Researchers must utilize advanced analytical techniques, including high-performance liquid chromatography, liquid chromatography-mass spectrometry, and nuclear magnetic resonance spectroscopy, to generate qualitative and quantitative phytochemical fingerprints, ensuring that any botanical fraction used in preclinical or clinical studies is characterized by consistent concentrations of marker active compounds.

5.2.2. Disconnect Between In Vitro Assays and In Vivo Models

A major methodological deficit in natural product research is the routine extrapolation of high-dose *in vitro* cytotoxicity to *in vivo* efficacy. Preclinical studies frequently treat tumor cell lines with micromolar concentrations of phytochemicals to show pathway inhibition and apoptosis induction [24]. However, pharmacokinetic studies show that due to poor aqueous solubility, low enterocyte permeability, and active efflux by ABC transporters, maximum attainable plasma concentrations in humans rarely exceed low nanomolar levels [26], [31]. Compounds such as resveratrol and curcumin are rapidly metabolized by intestinal and hepatic UDP-glucuronosyltransferases and sulfotransferases, transforming the active parent molecules into inactive, highly hydrophilic glucuronide and sulfate conjugates [28]. Evaluating parent phytochemicals in cell cultures at concentrations that are physically impossible to achieve *in vivo* creates a false impression of therapeutic potential, failing to account for the reality that the parent compound is cleared before it can reach the tumor site.

5.3. Clinical Trial Design for Genotype-Stratified Phytotherapy

5.3.1. Pharmacogenomic Co-enrollment Protocols

To transition ethnopharmacogenomics from an exploratory preclinical discipline to an evidence-based clinical practice, clinical trials must incorporate prospective pharmacogenomic stratification [40]. Standard clinical trials evaluating herbal interventions typically

treat unselected patient populations, averaging out any potential therapeutic signals and rendering the data uninterpretable due to high inter-individual variability. Future trial designs must co-enroll patients based on their germline ADME genomic variants (such as CYP2D6, CYP3A4, and ABCG2 polymorphisms) and the somatic mutational profiles of their tumors [40]. By tracking systemic drug exposure via serial pharmacokinetic sampling in patients with defined metabolizer phenotypes, researchers can distinguish between non-responsiveness caused by rapid clearance and genuine pharmacodynamic resistance, thereby establishing clear relationships between genotype, systemic exposure, and tumor response.

5.3.2. Endpoints and Reproducibility in Phytomedicine Trials

Clinical studies of plant-derived therapeutics must utilize objective, clinically relevant endpoints, such as progression-free survival, overall survival, and radiographically measured tumor regression, rather than relying on subjective quality-of-life scores or unvalidated biomarkers. The reproducibility of these trials is dependent on the complete transparency of the investigational product's manufacturing history. Trials must document the exact plant part utilized, the extraction methodology, the percentage of active marker compounds, the absence of heavy metal or microbial contamination, and the batch-to-batch consistency metrics [41]. Adherence to the Consolidated Standards of Reporting Trials (CONSORT) extension for herbal interventions is essential for ensuring that clinical data generated in resource-limited settings can withstand international scientific scrutiny and be integrated into global oncology databases.

Table 5. Clinically Significant Herb-Drug Interactions (HDIs) in Oncology

Botanical Extract Source	Dominant Bioactive Constituent	Affected Chemotherapy Substrate	Primary Pharmacokinetic / Pharmacodynamic Mechanism	Clinical Toxicity	References
St. John's Wort (*Hypericum perforatum*)	Hyperforin, Hypericin	Irinotecan, Docetaxel, Imatinib	PXR-mediated transcriptional upregulation of *CYP3A4* and *ABCB1* (P-gp) expression	Accelerated systemic clearance of chemotherapy, sub-therapeutic plasma drug concentrations, profound clinical treatment failure	[44]
Goldenseal / Berberis (*Hydrastis canadensis*)	Berberine	Paclitaxel, Doxorubicin, Cyclophosphamide	Potent competitive inhibition of hepatic CYP2D6 and CYP3A4 metabolic pathways	Impaired elimination of chemotherapy, systemic accumulation of toxic parent drugs, increased myelosuppression and severe neutropenic sepsis	[30], [43]
Green Tea Extract (*Camellia sinensis*)	Epigallocatechin gallate (EGCG)	Bortezomib, Fluorouracil, Doxorubicin	Direct chemical chelation (boronic acid binding) and competitive inhibition of *ABCG2*	Direct chemical inactivation of proteasome inhibitors, decreased tissue transport, altered therapeutic index	[18], [43]
Ginkgo Biloba (*Ginkgo biloba*)	Ginkgolides A/B, Bilobalide	Alkylating agents, Paclitaxel, Warfarin	Antagonism of platelet-activating factor (PAF) receptor; mild inhibition of CYP2C9	Severe localized hemorrhagic events, compromised platelet aggregation, unpredictable pharmacodynamic drug interactions	[43]
Grapefruit Juice (*Citrus paradisi*)	Furanocoumarins (Dihydroxybergamottin)	Docetaxel, Sunitinib, Erlotinib	Irreversible mechanism-based inactivation of intestinal enterocyte *CYP3A4* enzymes	Abolished intestinal first-pass clearance, massive spikes in oral drug bioavailability, severe diarrhea, and toxic cytopenia	[29], [43]

5.4. Herb–Drug Interactions in Oncological Care

5.4.1. Cytochrome P450 and Transporter Modulation

The concurrent use of traditional botanical medicines and conventional chemotherapy is highly prevalent among cancer patients globally, yet it is rarely disclosed to treating oncologists [42]. This concurrent consumption introduces a severe risk of clinically significant herb-drug interactions. Many heavily utilized phytochemicals are potent modulators of host drug-metabolizing enzymes and transport proteins. For example, berberine acts as both a substrate and a competitive inhibitor of CYP2D6 and CYP3A4, while curcumin has been shown to suppress the activity of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) [43]. Co-administering these compounds with narrow-therapeutic-index chemotherapeutics that utilize the same clearance pathways, such as doxorubicin, paclitaxel, or irinotecan, can lead to unpredictable changes in systemic drug levels.

5.4.2. Mechanisms of Therapeutic Failure and Toxicity

The molecular mechanisms driving herb-drug interactions can result in either catastrophic therapeutic failure or severe systemic toxicity. The induction of hepatic enzymes and efflux transporters represents a primary pathway for therapeutic failure [44]. Compounds such as hyperforin from St. John's Wort bind to the pregnane X receptor, triggering the transcriptional upregulation of CYP3A4 and ABCB1, which accelerates the clearance of active chemotherapeutic agents and reduces their systemic concentrations below the therapeutic threshold [44]. Conversely, the potent inhibition of these same clearance pathways by polyphenols or alkaloids can impair the elimination of conventional drugs, leading to accumulation in systemic circulation and precipitating dose-limiting toxicities, including severe myelosuppression, neutropenic sepsis, and peripheral neuropathy. A systematic categorization of these pharmacokinetic pathways is vital for protecting patient safety in integrated cancer care.

6. Ethical Dimensions of Using Traditional Knowledge with Genomic Science

6.1. Intellectual Property and Equitable Benefit-Sharing

6.1.1. Implementation of the Nagoya Protocol

The integration of traditional medicinal knowledge into modern genomics-driven drug discovery programs must operate under a robust legal and ethical framework to prevent the exploitation of indigenous communities. Historically, researchers from high-income countries have extracted traditional botanical knowledge from resource-limited regions, isolated the active chemical scaffolds, and secured lucrative international patents without providing compensation or recognition to the original knowledge-holders [45]. To mitigate this biopiracy, research programs must strictly adhere to the Nagoya Protocol on Access and Benefit-Sharing [45]. This international treaty requires researchers to obtain Prior Informed Consent from both national authorities and local indigenous communities before accessing genetic resources or associated traditional knowledge. Researchers must negotiate Mutually Agreed Terms that outline how the benefits arising from the commercialization or scientific advancement of the research will be shared with the source communities.

6.1.2. Mitigating Biopiracy and Knowledge Extraction

Ethical research practice requires a transition from extractive bioprospecting to collaborative, capacity-building partnerships. Indigenous knowledge-holders must be recognized as active intellectual partners rather than merely passive sources of empirical information. This involves the co-development of research agreements that protect local intellectual property rights and ensure that any technological advancements, such as high-throughput phytochemical profiling or computational modeling platforms, are shared with local academic institutions [35]. Benefit-sharing arrangements must include non-monetary provisions, such as training local scientists, investing in regional laboratory infrastructure, and ensuring that any therapeutic interventions developed from the collaborative research are made physically and economically accessible to the source populations.

6.2. Genomic Data Governance in Vulnerable Populations

6.2.1. Consent and Participant Autonomy

Genomic research involving patient populations in low- and middle-income countries presents unique ethical challenges regarding data privacy, storage, and downstream utilization. Because genomic data is uniquely identifiable, persistent, and transgenerational, standard one-time, broad consent models are increasingly recognized as ethically insufficient [40]. To protect participant autonomy, researchers should implement dynamic consent models [40]. These digital or community-mediated frameworks utilize ongoing, iterative communication to allow participants to modify their consent preferences over time. Participants can selectively grant or withdraw permission for secondary analyses, international data sharing, or commercial partnerships as the research project evolves.

This model is particularly critical in settings where low health literacy and language barriers may lead to therapeutic misconceptions, ensuring that consent is treated as an active, continuous relationship rather than a single administrative transaction.

6.2.2. Preventing Genomic Colonialism

The international transfer of biological samples and genomic data from resource-limited countries to high-income research hubs introduces the risk of genomic colonialism [36]. In these extractive dynamics, local researchers and patient populations provide the raw biological materials, while foreign institutions perform the high-depth sequencing, control the downstream databases, and claim primary authorship and intellectual property rights. Preventing this inequity requires the establishment of strict data sovereignty protocols [36]. Local institutional review boards must retain oversight of how genomic data is stored and shared, mandating that copy-number and raw sequence data remain hosted on regional servers whenever technically feasible. Collaborative projects must require the active involvement of local scientists in bioinformatics analyses, manuscript preparation, and patent applications, ensuring that local research institutions build the capacity to perform independent genomic research.

6.3. Epistemic Justice in Global Health Research

6.3.1. De-centering Western Biomedical Reductionism

Epistemic justice in global health requires recognizing traditional medicine as a valid, self-sustaining system of knowledge with its own internal logic, observation methodologies, and therapeutic philosophies, rather than treating it merely as a reservoir of unrefined raw materials awaiting validation by Western science [35]. The dominant biomedical paradigm frequently exhibits epistemic prejudice by reducing complex traditional formulations—which may rely on synergistic interactions, holistic patient care, and specific preparation rituals—into isolated, single-molecule chemical scaffolds [35]. This reductionism can lead to the cultural erasure of the traditional healers and indigenous communities who have developed and preserved these medical systems over centuries.

6.3.2. Participatory Co-production of Knowledge

Cultivating an ethically sound translational pipeline necessitates the active co-production of knowledge between laboratory scientists and traditional practitioners. This collaborative approach requires mutual humility, where molecular biologists and traditional healers design research protocols together, respecting both the empirical observations of traditional practice and the safety and validation requirements of modern pharmacology [35]. Traditional practitioners must be included in scientific publications, and research results must be disseminated back to local communities in culturally and linguistically accessible formats. By prioritizing participatory research models, ethnopharmacogenomics can avoid repeating historical patterns of intellectual marginalization and instead promote a more equitable, inclusive paradigm for global oncology innovation.

7. Translational and Research Priorities

7.1. Priority Research Directions

7.1.1. Standardized Phytochemical Profiling in Cohort Studies

The immediate progress of ethnopharmacogenomics relies on linking clinical pharmacology with advanced analytical chemistry rather than continuing to generate redundant *in vitro* screening data. Research designs must incorporate standardized phytochemical profiling directly into patient cohort studies [39]. Investigators should recruit cohorts of cancer patients who are already consuming specific botanical preparations and systematically profile their germline ADME genomic variants, including cytochrome P450 polymorphisms and transport protein genotypes [40]. Rather than relying on botanical classification alone, the exact herbal batches administered to these cohorts must undergo quantitative characterization using high-performance liquid chromatography and mass spectrometry [39]. By measuring parent phytochemical and Phase-II metabolite concentrations in serial blood samples, researchers can map true human pharmacokinetic curves and correlate systemic exposure with clinical outcomes [40]. This strategy clarifies how host genetic variation influences the disposition of natural compounds in real-world settings, resolving the disconnect between cell culture assays and clinical realities.

7.1.2. Genotype-Specific Clinical Assessments

To establish the clinical validity of plant-derived compounds, future clinical trials must transition away from all-comer designs and adopt genotype-specific stratification protocols [40]. If a phytochemical like berberine or epigallocatechin gallate shows high-affinity pathway modulation in preclinical models, its therapeutic efficacy must be evaluated in patient cohorts pre-selected for specific somatic tumor mutations, such as PIK3CA mutations, KRAS alterations, or TP53 mutations [40]. This stratification separates patients with pathway-specific vulnerabilities from those with drug-resistant tumor architectures, allowing researchers to determine

if the natural scaffold operates as a targeted therapeutic or a non-specific cytotoxic agent. These trials must utilize objective, radiographically validated endpoints such as progression-free survival and overall survival, adhering strictly to the Consolidated Standards of Reporting Trials extension for herbal interventions to ensure global scientific acceptance [41].

7.2. Regulatory Development and Quality Control

7.2.1. Alignment with the WHO Global Traditional Medicine Strategy

The translation of ethnopharmacological resources into clinical practice must align with the World Health Organization Global Traditional Medicine Strategy 2025–2034. This international framework directs member states to establish structured, risk-based regulatory oversight of traditional and complementary medicines to ensure public safety and product quality. For oncology patients, who often exhibit physiological fragility and receive complex, narrow-therapeutic-index systemic therapies, regulatory stewardship is essential. National regulatory bodies must transition from informal tolerance of traditional medicines to active administrative governance, establishing clear legal definitions for botanical products and regulating their clinical evaluation according to the same safety standards applied to synthetic drug candidates.

Table 6. Quality Assurance Standards and Regulatory Metrics for Botanical Formulations

Quality Domain	Required Analytical Technology	Standard Operating Procedure	Target Validation Metric	Direct Relevance to WHO Global Strategy (2025–2034)	References
Phytochemical Standardization	HPLC-DAD / LC-MS / Quantitative NMR	Multi-marker profiling and chemical finger-printing of active botanical components	Baseline concentration thresholds for verified index compounds (e.g., total curcuminoids ≥ 95.0%)	Eliminates batch-to-batch chemical heterogeneity; guarantees dosing reproducibility in clinical trial cohorts	[39], [41]
Species Authentication	DNA Barcoding / Pharmacognostical Micro-characterization	Sequencing of plastid gene regions (*matK*, *rbcL*, or nuclear *ITS2*)	100% genomic sequence matching with verified reference vouchers	Excludes accidental species substitution, product mislabeling, and intentional adulteration with toxic look-alikes	[39]
Chemical Contamination Control	ICP-MS / Gas Chromatography-MS	Quantitative heavy metal, pesticide, and mycotoxin screening	Mercury < 0.1 ppm, Lead < 5.0 ppm, Arsenic < 2.0 ppm; zero trace organophosphates or aflatoxins	Protects highly fragile, immunocompromised oncology patients from organ toxicity and compounding toxicities	[41]
Preclinical Characterization	High-throughput *in vitro* assays & *in vivo* animal ADME profiling	Mandatory PAINS filter screening, cell viability comparison, and oral bioavailability assays in rodent models	Indication of micromolar target engagement *in vivo* without toxic biochemical aggregation or assay artifacts	Dismantles unverified anticancer claims; enforces rigorous scientific accountability before initiating human trials	[40]
Clinical Efficacy Standardization	Randomized, Placebo-controlled Genotype-stratified Trials	Prospective patient cohort enrollment based on germline ADME profiles and tumor somatic mutations	Adherence to CONSORT Extension for Herbal Interventions; objective progression-free survival (PFS) endpoints	Establishes reproducible, evidence-based integration of botanical drugs within international health systems	[40], [41]

7.2.2. Quality Assurance and Complex Botanical Drug Standards

Registering multi-component botanical preparations requires regulatory agencies to develop adaptive evaluation frameworks that diverge from single-molecule synthetic drug criteria. Because plant extracts contain dozens of active and inactive constituents that may exhibit interactive pharmacodynamic properties, regulatory protocols must mandate rigorous quality assurance standards. These standards must include qualitative and quantitative chromatographic fingerprinting to verify batch-to-batch consistency and species authenticity [39]. Regulatory guidelines must enforce strict thresholds for contamination, requiring systematic screening for heavy metals, pesticide residues, microbial pathogens, and mycotoxins [41]. Establishing these rigid quality metrics is an indispensable prerequisite for protecting patient safety and ensuring that investigational botanical products yield reproducible results across multi-center clinical trials.

7.3. Health System Integration and Harm Reduction

7.3.1. Clinical Communication and Interaction Screening

Because concurrent traditional medicine use is highly prevalent among cancer patients but rarely disclosed to treating oncologists, the immediate goal of healthcare systems must be risk mitigation through non-punitive, structured communication [42]. Oncology clinics must establish standardized intake protocols where healthcare providers routinely ask patients about their supplement and herbal consumption using open, culturally sensitive language. Clinical pharmacists must be integrated into this workflow, using specialized pharmacokinetic databases to screen for potential herb-drug interactions, particularly the modulation of CYP3A4, CYP2D6, ABCB1, or ABCG2 by heavily consumed phytochemicals [43]. This clinical screening provides immediate safety benefits, allowing patients to modify their herbal intake during active chemotherapy windows to prevent treatment failure or catastrophic systemic toxicities [44].



Figure 4. Herb-Drug-Pharmacogenomic Interaction Matrix

7.3.2. Pharmacovigilance and Multi-Sectoral Cooperation

Developing safe clinical integration requires the establishment of localized pharmacovigilance pathways that systematically capture, analyze, and report adverse events linked to botanical formulations. This objective demands active, multi-sectoral cooperation between oncology centers, academic pharmacology departments, traditional practitioners, and national regulatory authorities. By building cooperative clinical networks, healthcare systems can monitor toxicities in real time, identify contaminated product batches,

and document suspected herb-drug interactions within formal databases. Engaging traditional practitioners directly in these safety networks encourages mutual clinical respect, helping to build referral systems that discourage patients from delaying evidence-based oncological care in favor of unvalidated botanical therapies.

8. Conclusion

The use of ethnopharmacological knowledge with modern cancer research and host pharmacogenomics is a rigorous, scientifically viable pathway for drug discovery and patient safety, particularly in settings underserved by conventional targeted biologics. To achieve clinical utility, the translational pipeline must discard the assumption that high-dose *in vitro* screening data translates directly to clinical efficacy, recognizing that the primary bottleneck to therapeutic success is inherently poor baseline oral bioavailability, rapid Phase-II conjugation, and chemical instability rather than minor genetic variations in host metabolism. Overcoming these challenges requires mandatory quality control standards, including multi-marker chromatographic fingerprinting, alongside the implementation of genotype-stratified clinical trial designs that evaluate well-characterized botanical compounds against specific host ADME profiles and tumor somatic mutations. This integration must operate under a robust legal and ethical framework that secures data sovereignty, protects vulnerable populations from genomic colonialism, and ensures equitable benefit-sharing in strict compliance with the Nagoya Protocol. Traditional practitioners and indigenous communities must be engaged as active intellectual partners in the co-production of knowledge rather than being treated as passive sources of empirical information. When grounded in physical chemistry, molecular pharmacology, and legal ethics, the convergence of traditional medicine and genomic science provides an objective, epistemologically just framework to mitigate herb-drug toxicities, discover novel chemical scaffolds, and support contextually appropriate cancer care globally.

References

[1] Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249.

[2] Tang, X., Di, Y., Lim, H. J., & Tan, A. C. (2024). Precision oncology: Current and future platforms for treatment selection. Trends in Cancer, 10(9), 781-791.

[3] Radich, J. P., Cole, L. D., & Inaba, H. (2022). Precision medicine in low- and middle-income countries. Annual Review of Pathology: Mechanisms of Disease, 17, 387-402.

[4] Hirko, K. A., Rocque, G., & Reeder-Hayes, K. (2022). Addressing global cancer care inequities using implementation science approaches. EMJ Innovations, 6(1), 45-52.

[5] Miya, T. V., Temane, A., & Ndou, N. (2025). Traditional medicine, environmental exposures, and cultural practices in cancer risk: A systematic review. Frontiers in Oncology, 15, 1623895.

[6] Adam, A. S., Bangalee, V., & Oosthuizen, F. (2024). The use of traditional and complementary medicine by cancer patients in sub-Saharan Africa: A scoping review. Health SA Gesondheid, 29, 2743.

[7] Agu, P. C., Chukwuanukwu, R. C., & Okoye, E. L. (2025). Historical and ethnopharmacological perspectives on African medicinal plants. Scientific African, 30, e02941.

[8] Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971). Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. Journal of the American Chemical Society, 93(9), 2325-2327.

[9] Liu, M. Z., Zhang, Y. L., Zeng, M. Y., He, F. Z., Xu, Q., & Yuan, L. (2015). Pharmacogenomics and herb-drug interactions: Merge of future and tradition. Evidence-Based Complementary and Alternative Medicine, 2015, 321091.

[10] Singh, M., Sharma, R., & Kumar, A. (2024). Pharmacogenomics studies of traditional medicine: Exploring the genetic basis of plant therapeutics. African Journal of Biological Sciences, 6(9), 1171-1196.

[11] Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of Natural Products, 83(3), 770-803.

[12] Dehelean, C. A., Marcovici, I., Soica, C., Mioc, M., Coricovac, D., Iurciuc, S., & Cretu, F. M. (2021). Plant-derived anticancer compounds as new perspectives in drug discovery. Molecules, 26(4), 1109.

[13] Wall, M. E., & Wani, M. C. (1995). Camptothecin and taxol: From discovery to clinic. Journal of Natural Products, 58(1), 129-133.

[14] Noble, R. L. (1990). The discovery of the vinca alkaloids—chemotherapeutic agents against cancer. Biochemistry and Cell Biology, 68(12), 1344-1351.

[15] Tillhon, M., Guaman Ortiz, L. M., Lombardi, P., Scovassi, A. I., & Prosperi, E. (2012). Berberine: New perspectives for old remedies. Biochemical Pharmacology, 84(10), 1260-1267.

[16] Aggarwal, B. B., Sung, B., & Kunnumakkara, A. B. (2009). Curcumin and cancer: An "old-age" disease with an "age-old" solution. Cancer Letters, 267(1), 133-164.

[17] Baur, J. A., & Sinclair, D. A. (2006). Therapeutic potential of resveratrol: The *in vivo* evidence. Nature Reviews Drug Discovery, 5(6), 493-506.

[18] Yang, C. S., Wang, X., Lu, G., & Picinich, S. C. (2009). Cancer prevention by green tea: Evidence from laboratory, clinical, and epidemiological studies. Cancer Prevention Research, 2(11), 914-922.

[19] Vyas, A. R., & Singh, S. V. (2014). Molecular targets and mechanisms of cancer prevention and treatment by withaferin A. AAPS Journal, 16(1), 1-10.

[20] Nag, S. A., Qin, J. J., Wang, W., Wang, M. H., Wang, H., & Zhang, R. (2012). Ginsenosides as anticancer agents: *In vitro* and *in vivo* activities, structure-activity relationships, and molecular mechanisms of action. Frontiers in Pharmacology, 3, 25.

[21] Thomson, M., & Ali, M. (2003). Garlic [*Allium sativum*]: A review of its potential use as an anti-cancer agent. Current Cancer Drug Targets, 3(1), 67-81.

[22] Samuels, Y., & Ericson, K. (2006). Oncogenic mutations of PIK3CA in human cancers. Current Topics in Microbiology and Immunology, 347, 21-41.

[23] Cox, A. D., Fesik, S. W., Kimmelman, A. C., Babbitt, J., & Der, C. J. (2014). Drugging the undruggable RAS: Mission possible? Nature Reviews Drug Discovery, 13(11), 828-851.

[24] Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., ... & Futreal, P. A. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949-954.

[25] Baell, J. B., & Holloway, G. A. (2010). New substructure filters for removal of pan-assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. Journal of Medicinal Chemistry, 53(7), 2719-2740.

[26] Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics, 4(6), 807-818.

[27] Griesser, M., Pistis, V., Suzuki, T., Tejera, N., Pratt, D. A., & Albert, A. (2011). Autoxidative degradation of curcumin under physiological conditions. Chemical Research in Toxicology, 24(9), 1451-1458.

[28] Hanioka, N., Naito, T., & Narimatsu, S. (2012). Human UDP-glucuronosyltransferase isoforms involved in the glucuronidation of resveratrol and dietary polyphenols. Phytotherapy Research, 26(6), 844-851.

[29] Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics, 138(1), 103-141.

[30] Tan, X. S., Ma, J. Y., & Feng, R. (2013). Pharmacokinetics and cytochrome P450-mediated metabolism of berberine in humans. Xenobiotica, 43(12), 1075-1083.

[31] Gottesman, M. M., Fojo, T., & Bates, S. E. (2002). Multidrug resistance in cancer: Role of ATP-dependent transporters. Nature Reviews Cancer, 2(1), 48-58.

[32] Meng, X. Y., Zhang, H. X., Mezei, M., & Cui, M. (2011). Molecular docking: A powerful approach for structure-based drug discovery. Current Computer-Aided Drug Design, 7(2), 146-157.

[33] Sorokina, M., Merseburger, P., Rajan, K., Yirik, M. A., & Steinbeck, C. (2021). COCONUT, the COlleCtion of Open Natural ProdUcts. Journal of Cheminformatics, 13(1), 2.

[34] Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: Methods and applications. Nature Reviews Drug Discovery, 3(11), 935-949.

[35] Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682-690.

[36] Poornima, P., Weng, C. F., & Padma, V. V. (2016). Network pharmacology-based prediction of active compounds and mechanisms of traditional medicines. Phytomedicine, 23(12), 1340-1348.

[37] Lavecchia, A. (2015). Machine-learning approaches in drug discovery: Methods and applications. Drug Discovery Today, 20(3), 318-331.

[38] Sheridan, R. P. (2013). Three scenarios for generalizability in machine learning models of compound activity. Journal of Chemical Information and Modeling, 53(11), 2837-2844.

[39] Salem, M. A., Perez de Souza, L., Serag, A., Fernie, A. R., Farag, M. A., & Alseekh, S. (2020). Metabolomics in the context of plant natural products research: From sample preparation to metabolite characterization. Metabolites, 10(1), 37.

[40] Chandan, T. R., & Prasad, S. (2025). Pharmacogenomics and personalized medicine: A revolution in oncology drug therapy. Research Journal of Pharmacology and Pharmacodynamics, 17(4), 311-318.

[41] Gagnier, J. J., Boon, H., Rochon, P., Moher, D., Barnes, J., & Bombardier, C. (2006). Reporting randomized, controlled trials of herbal interventions: An elaborated CONSORT statement. Annals of Internal Medicine, 144(5), 364-367.

[42] Ouko, J. O., & Maina, P. K. (2024). Ethnobotanical assessment of herbal medicine practices for cancer treatment in East Africa. African Journal of Empirical Research, 5(3), 1149-1165.

[43] Duan, X., Wang, Y., & Zhang, L. (2025). Herb-drug interactions in oncology: Pharmacodynamic/pharmacokinetic mechanisms and risk prediction models. Chinese Medicine, 20, 107.

[44] Moore, L. B., Goodwin, B., Jones, S. A., Wisely, G. B., Serabjit-Singh, C. J., Willson, T. M., ... & Kliewer, S. A. (2000). St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proceedings of the National Academy of Sciences, 97(13), 7500-7502.

[45] Rahman, P., & Mehnaz, S. (2024). Traditional knowledge in drug development and the rights of indigenous peoples: Implementation of the Nagoya Protocol. SSRN Electronic Journal, 478291.